60814-16-6

Basic information

• Product Name: 2-(4-Nitrophenoxy)ethylamine
• Synonyms: 2-(4-Nitrophenoxy)ethylamine;2-(4-nitrophenoxy)ethanamine;2-(4-Nitrophenoxy)-1-ethanamine;2-(p-Nitrophenoxy)ethylamine;2-Aminoethyl 4-nitrophenyl ether
• CAS NO: 60814-16-6
• Molecular Formula: C₈H₁₀N₂O₃
• Molecular Weight: 182.1766
• Mol File: 60814-16-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 29-30℃
• Boiling Point: 345.1°C at 760 mmHg
• Flash Point: 162.5°C
• Appearance: /
• Density: 1.252
• Vapor Pressure: 6.3E-05mmHg at 25°C
• Refractive Index: 1.568
• CAS DataBase Reference: 2-(4-Nitrophenoxy)ethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Nitrophenoxy)ethylamine(60814-16-6)
• EPA Substance Registry System: 2-(4-Nitrophenoxy)ethylamine(60814-16-6)

Safety Data

• Hazardous Substances Data: 60814-16-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H10N2O3/c9-5-6-13-8-3-1-7(2-4-8)10(11)12/h1-4H,5-6,9H2

Upstream product

• 3383-72-0 1-(2-chloroethoxy)-4-nitrobenzene 
• 98395-61-0 N-(2-(4-nitrophenoxy)ethyl)phthalimide 
• 100-02-7 4-nitro-phenol 
• 141-43-5 ethanolamine 
• 350-46-9 4-Fluoronitrobenzene 
• 159184-13-1 1-(2-Azidoethoxy)-4-nitrobenzene 
• 7285-11-2 chloroform methanol 

Downstream Products

• 860032-83-3 5-[(R)-2-(2-{4-[4-(2-amino-ethoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one 
• 1613189-32-4 C₄₀H₅₀N₄O₄Si 
• 72210-18-5 4-(2-amino-ethoxy)-aniline 
• 159184-14-2 2-(4-Nitrophenoxy)ethylcarbamic acid 1,1-dimethylethyl ester 
• 111624-98-7 2-Isopropyl-5-[2-(4-nitro-phenoxy)-ethylamino]-2-(3,4,5-trimethoxy-phenyl)-pentanenitrile 
• 111625-04-8 5-[2-(4-Amino-phenoxy)-ethylamino]-2-isopropyl-2-(3,4,5-trimethoxy-phenyl)-pentanenitrile 
• 1965-54-4 N-(2-hydroxyethyl)-4-nitroaniline 
• 138803-37-9 1-(6-Chloro-pyridazin-3-yloxy)-3-[2-(4-nitro-phenoxy)-ethylamino]-propan-2-ol 

Relevant articles and documents

Diphenylamino pyrimidine compound for inhibiting kinase activity

The invention provides a diphenylamino pyrimidine compound for inhibiting the kinase activity, and particularly provides a medicinal composition of a substituted diphenylamino pyrimidine compound andapplication thereof. The compound is a compound as shown in a formula (I) in the specification, or pharmaceutically acceptable salt, prodrug, hydrate thereof or solvent compound, crystal form, N-oxideand various diastereomers thereof. The compound can be used for treating diseases which can be treated with JAK2 kinase inhibitors.

LIQUID CRYSTAL ALIGNING AGENT

Provided is a liquid crystal aligning agent capable of forming a liquid crystal alignment film the surface of which is rarely scratched or abraded when rubbed, and which exhibits excellent liquid crystal aligning properties and enables the production of l

Synthesis and evaluation of novel phenylethanolamine derivatives containing acetanilides as potent and selective b 3-adrenergic receptor agonists

In the search for potent and selective human β3-adrenergic receptor (AR) agonists as potential pharmacotherapies for the treatment of obesity and non-insulin dependent (type II) diabetes, we prepared a novel series of phenylethanolamine derivatives containing acetanilides and evaluated their biological activities at the human β3-, β2-, and β1-ARs. Among these compounds, the 6-amino-2-pyridylacetanilide (36b), 2-amino-5- methylthiazol- 4-ylacetanilide (36g), and 5-amino-1,2,4-thiadiazol-3- ylacetanilide (36h) derivatives showed potent agonistic activity at the β3-AR with functional selectivity over the β1- and β2-ARs. In addition, these compounds exhibited significant hypoglycemic activity in a rodent diabetic model.